source
- Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlookSarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Sev…
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…